Efthymios N. Deliargyris

Showing 1-4 of 4 articles

Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials

Vaduganathan M, Harrington R, Stone G, Steg P, Gibson CM, Hamm C, Price M, Lopes R, Leonardi S, Deliargyris E, Prats J, Mahaffey K, White H, Bhatt D

February 2, 2018 | 10.4244/EIJ-D-17-00723

Coronary interventions

Bivalirudin infusion to reduce ventricular infarction: the open-label, randomised Bivalirudin Infusion for Ventricular InfArction Limitation (BIVAL) study

van Geuns R, Sideris G, van Royen N, El Mahmoud R, Diletti R, Sollier C, Garot J, Van Der Hoeven N, Cortese B, Ding L, Lechthaler I, Deliargyris E, Anthopoulos P, Drouet L

August 4, 2017 | 10.4244/EIJ-D-17-00307

Impact of antithrombotic treatment on short-term outcomes after percutaneous coronary intervention for left main disease: a pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials

Geisler T, Müller K, Karathanos A, Bocksch W, Gawaz M, Deliargyris E, Bernstein D, Lincoff A, Mehran R, Dangas G, Stone G

May 20, 2014 | 10.4244/EIJV10I1A16

Bivalirudin versus unfractionated heparin in percutaneous coronary interventions of patients having received initial fondaparinux treatment: a propensity matched study

Hamon M, Rao S, Steg G, Valgimigli M, Verheugt F, Marso S, Gershlick A, Wang Y, Deliargyris E

August 24, 2012 | 10.4244/EIJV8I4A76

1

Latest news

State of the Art on ViV-TAVI; Transseptal Punctures; Endovascular Closure and TF-TAVI; Percutaneous PVL Closure: Long-Term Outcomes; and more

October 20, 2021

STATE OF THE ART

Valve-in-valve TAVI: a practical overview

Giuseppe Tarantini et al.

October 20, 2021

TAVI in younger (<70 years old) patients: the AMTRAC registry

Guy Witberg et al.

October 22, 2021

Impact of LVOT calcification in transfemoral TAVI patients

L. Waldschmidt et al.

October 19, 2021

My Stroke Story

October 20, 2021

Impact of preprocedural biological markers on 10-year mortality in the SYNTAXES trial

Hironori Hara et al.

October 22, 2021

Serum caffeine causes adenosine-induced FFR overestimation

Hideaki Tanaka et al.

October 15, 2021

Valvular disease